Summary
The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects.
Each subject took nifurtimox 15 mg·kg−1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC.
The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed.
The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
WHO Technical Report Series 202 (1960)
Schenone H, Villarroel F, Rojas A, Alfaro E (1980) Factores biológicos y ecológicos de la enfermedad de Chagas en Chile. Bol Chile Parasit 35: 42–54
Webster LT (1985) Drug used in the chemotherapy of protozool infections. In: AG Gilman, LS Goodman, TW Rall, F Murad (eds). The pharmacological basis of therapeutics, MacMillan Publication Co, New York, 7th edn, pp 1060–1078
Bock M, Gonnert R, Haberkorn A (1969) Studies with Bay 2502 in animals. Bol Chile Parasit 24: 13–16
Docampo R, Moreno SNJ (1984) Free radical metabolites in the mode of action of chemotherapeutics agents and phagocytic cells on Trypanosoma cruzi. Rev Infect Dis 6: 223–238
Brener Z (1979) Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western hemisphere. Pharmacol Ther 7: 71–90
Laplume H, Barousse A, Cabrera H (1982) Effectos indeseables de nifurtimox y benznidazole. Medicina (Buenos Aires) 42: 55–58
Thambo S, Passalacqua W, Lazcano S (1989) Enfermedad de Chagas y transplante renal. Rev Méd Chile 117: 18–22
Paulos C, Thambo S, Paredes J, Vásquez I, González-Martin G (1989) Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 27: 454–457
Paulos C, Paredes J, Vásquez I, Kunze G, González-Martin G (1988) High performance liquid chromatographic determination of nifurtimox in human serum. J Chromatogr (Biomed Appl) 433: 359–362
Stolley PD, Strom BL (1986) Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 39: 489–490
Duhm B, Maul W, Medenwall H, Patzchke K, Wegner L (1972) Investigation of nifurtimox-S 35 in the rat and the dog. Arzneim Forsch 22: 1617–1623
Medenwald H, Brandau K and Schlossmann K (1972) Quantitative determination of nifurtimox in body fluids of rat, dog and man. Arzneim Forsch 22: 1613–1616
Reindenberg MM (1977) The biotransformation of drugs in renal failure. Am J Med 62: 482–484
Masana M, Toranzo EGD, Castro JA (1984) A study on nifurtimox nitroreductase activity in liver and other rat tissues. Arch Int Pharmacodyn Ther 270: 4–10
Toranzo EGD, Masana M, Castro J. A (1983) Nitroreduction of benzmidazole and nifurtimox by rat and human feces. Res Commun Chem Pathol Pharmacol 41: 341–344
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
González-Martin, G., Thambo, S., Paulos, C. et al. The pharmacokinetics of nifurtimox in chronic renal failure. Eur J Clin Pharmacol 42, 671–673 (1992). https://doi.org/10.1007/BF00265935
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00265935